Barry Fishman
Director/Board Member bij FIELD TRIP HEALTH & WELLNESS LTD.
Vermogen: - $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Joseph del Moral | M | 45 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 jaar |
Jeff Watson | M | - |
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: MajorHealth Technology Apotex, Inc. operates as a generic pharmaceutical company that offers medicines. It engages in research and development, bioequivalence, and clinical studies. The company was founded by Dr. Bernard Sherman in 1974 and is headquartered in Toronto, Canada. | 31 jaar |
Allan Grant Oberman | M | 66 |
Teva Canada Ltd.
Teva Canada Ltd. Pharmaceuticals: GenericHealth Technology Part of Teva Pharmaceutical Industries Ltd., Teva Canada Ltd. is a Canadian company that deeply cares about the wellbeing of patients, caregivers, and communities. The private company serves 200 million people every day, offering a unique perspective on health through their leadership in generic and brand-name medicines, as well as innovative solutions for healthcare partners. The company is based in Toronto, Canada. Sandy Lee's journey with Teva started in 1988 when she accepted a position as a secretary in Teva's regulatory affairs department.
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: MajorHealth Technology Apotex, Inc. operates as a generic pharmaceutical company that offers medicines. It engages in research and development, bioequivalence, and clinical studies. The company was founded by Dr. Bernard Sherman in 1974 and is headquartered in Toronto, Canada. | 10 jaar |
Gregory Mayes | M | 55 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 jaar |
Mather A. Carscallen | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | 9 jaar |
Jean Drouin | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Syed Mujeeb Jafferi | M | 41 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Amardeep Manhas | M | 41 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Maryann Adesso | F | - | - | |
Curtis Weber | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 jaar |
Araba Chintoh | M | - | - | |
Francis Lavelle | M | 75 | - | |
Onur Yildirim | M | - | - | |
Roar Askhein | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Dave Shekhter | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Pere Paton | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Sharon James | F | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Craig Behnke | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Leslie Ewing | F | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
William Ashton | M | - | - | |
Mark Mantel | M | - |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | 2 jaar |
Michael Verbora | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 4 jaar |
Carole Chan | F | - | 4 jaar | |
Alexander Shoghi | M | 43 | - | |
Larry Kaiser | M | 72 | - | |
Dieter Weinand | M | 63 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 4 jaar |
Ellen Lubman | F | 48 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 jaar |
Catalina Lopez-Correa | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Raza Bokhari | M | 57 | - | |
Keith Merker | M | 51 | - | |
Robert Ciaruffoli | M | 72 | - | |
Michael Coupland | M | - | - | |
Andrew Nichols | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Kristen Laguerre | F | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Nathan Bryson | M | 61 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 jaar |
Chet Lakhani | M | - | - | |
James Gale | M | 74 |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | - |
Monique Jeannette Moller | M | - | 2 jaar | |
Carolyn Bonner | F | 40 | - | |
Edward Smith | M | 53 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 jaar |
Robert Alexander | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 jaar |
Ansbert Gadicke | M | 66 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Jonathan See | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Tyler Burns | M | - | 8 jaar | |
Dave Matthews | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Edgar Diaz | M | - | - | |
James Quinlan | M | 60 | - | |
Edward Brennan | M | 64 | - | |
Fred Grossman | M | 62 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 jaar |
Hannan Fleiman | M | 44 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 5 jaar |
Donna Wong | F | 58 | - | |
Joel Mallard | M | - | 6 jaar | |
Jacob M. Kay | M | 83 |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | - |
Ryan Yermus | M | 43 | - | |
Elizabeth Wolfson | M | - | - | |
Stacey Hoisak | F | - | 2 jaar | |
Andreas Sander | M | - | 5 jaar | |
Craig Podolsky | M | - |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | - |
Huma Qamar | M | - | 1 jaar | |
Ian Jacobson | M | 64 |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | - |
Vicki Reed | F | - | - | |
Viktoriia Slepeniuk | F | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Bumby | M | 60 | - | |
Charles Rifici | M | 49 | 8 jaar | |
Richard Fitzgerald | M | - | 4 jaar | |
Christopher Schnarr | M | 57 | 6 jaar | |
Dave Guebert | M | 64 | 7 jaar | |
Raymond Laflamme | M | - | 5 jaar | |
John Bell | M | 77 | 6 jaar | |
Itzhak Krinsky | M | 71 | 1 jaar | |
Ronan Levy | M | 45 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Ken Clement | M | - | 11 jaar | |
Elie K. Farah | M | - | 3 jaar | |
Theresa Firestone | F | - | 3 jaar | |
Murray Goldman | M | - | 3 jaar | |
Robert Bloch | M | - | - | |
Robert J. Manzo | M | 66 | 3 jaar | |
Maurice Chagnaud | M | 63 | - | |
Daniel Laflamme | M | - | 2 jaar | |
Ray Thompson | M | 54 | 4 jaar | |
John Fowle | M | 46 | 3 jaar | |
Helen Boudreau | F | 58 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 jaar |
Rochelle Fuhrmann | F | 54 | 3 jaar | |
Paula Hewitt | F | 52 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Frank Perier | M | 64 | 1 jaar | |
Randall C. Benson | M | 64 | 2 jaar | |
Paul N. Lucas | M | 74 | 3 jaar | |
Robert Pollock | M | 54 | 6 jaar | |
Mark Iwanowski | M | 68 | 2 jaar | |
Frances Cloud | F | 59 | - | |
Phillip Shaer | M | 50 | 5 jaar | |
Aaron Keay | M | 47 | 4 jaar | |
Patrick Volkert Vink | M | 60 | 2 jaar | |
Douglas N. Deeth | M | 76 | 5 jaar | |
Tim Hayden | M | 45 | 3 jaar | |
Gary J. McMullen | M | - | 1 jaar | |
Andrew Patient | M | - | 5 jaar | |
Shekhar Parmar | M | - | 1 jaar | |
Sung Kang | M | - | 1 jaar | |
Jeffrey Henderson | M | 59 |
Eli Lilly Canada, Inc.
Eli Lilly Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Canada, Inc. is a healthcare leader that focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. The private company is based in Scarborough, Canada. Established in 1938, the Canadian company collaborates with scientists to produce innovative medicines that make life better for people around the world. The company's mission is to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to communities through philanthropy and volunteerism. | 7 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Canada | 77 | 77.00% |
Verenigd Koninkrijk | 9 | 9.00% |
Verenigde Staten | 3 | 3.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Barry Fishman
- Persoonlijk netwerk